950 Agents Ran for 21 Hours, and Claude Narrowed 200,000 Reverse Transcriptases Down to One CRISPR-Like Enzyme System

Anthropic announced a life sciences research group and laboratory on September 23 and published an early result: in autonomous analysis, Claude identified a previously uncharacterized enzyme system the company named array-associated reverse transcriptases, or ART. The system consists of a reverse transcriptase — an enzyme that copies RNA into DNA — an array of repeating DNA resembling patterns seen in CRISPR, and an accessory protein of unknown function, found primarily in bacteriophages, the viruses that infect bacteria. Preliminary experiments show the repeat array produces distinct short RNAs, suggesting possible CRISPR-like programmability, though Anthropic states plainly that it does not yet know the system's function. On scale, the work used roughly 950 agents over 21 hours, processing 210 million tokens, identifying 3,500 new candidate systems from more than 200,000 reverse transcriptases before concentrating on the 20 most compelling for detailed analysis — work the company says typically takes expert scientists weeks to months. On the division of labor, Anthropic says its human scientists' involvement was limited to writing the initial prompt and performing all laboratory work, with the model operating no experimental equipment. One attribution boundary needs stating: the underlying reverse transcriptase had already been identified in earlier research, in a study of a jumbo phage, and Claude appears to be the first to recognize the key features of the broader system. The Bay Area laboratory operates at biosafety levels BSL-1 and BSL-2 and handles no human pathogens; the research group was formed in spring 2026. The company released a pre-print and says independent testing is still required to determine whether the finding could transform gene editing, with the scientific community to give a final assessment of its novelty and significance. Outside researcher Zhang called it "an exciting example of how AI agents can contribute to biological discovery," adding that the identification of RNA-repeat arrays associated with reverse transcriptases merits further investigation.

State Precisely What Was Found

This story invites retelling as "AI discovered a new gene-editing tool." By the company's own materials the accurate description is far more restrained — and the restraint is meaningful. **The underlying reverse transcriptase had already been identified in earlier research**, in a study of a jumbo phage. What Claude appears to be first at is recognizing **the key features of the larger system**: that the enzyme sits beside an array of repeating DNA, along with an accessory protein of unknown function, forming a combination not previously characterized. "Unknown function" is not modesty either. Anthropic says outright that it does not know what ART does. The evidence for possible programmability is that preliminary experiments show the repeat array produces distinct short RNAs, and that this set of characteristics has only ever appeared together in a handful of known systems, all of which are programmable. **This is a lead worth chasing, not an established tool.** The company released a pre-print and says novelty and significance are for the scientific community to assess. Outside assessment currently sits at the same level: researcher Zhang called it an exciting example of how AI agents can contribute to biological discovery, and said the identification merits further investigation. "Merits further investigation" is an honest position.

950 Agents Over 21 Hours Is a Concrete Slice of a Number From Four Days Ago

On September 20 this site covered Anthropic's R&D automation index: 26% of its R&D work reached level 4 in August — humans set broad direction, AI performs most of the work on its own — with roughly 30,000 agents at any moment writing code and running experiments on its busiest internal platform. Today's story turns that abstraction into a sample you can look at: **roughly 950 agents, 21 hours, 210 million tokens, narrowing 200,000 reverse transcriptases to 3,500 candidates and then to 20 for detailed analysis.** Anthropic says work of that kind typically takes experts weeks to months. The shape of the process is what deserves attention. This was not "the model had an idea." It was **large-scale exhaustive search plus layered narrowing** — find everything findable, then filter by judgment, layer by layer. That is exactly what current agent systems are best at and what is least economical for humans: looking at 200,000 objects one by one is infeasible in labor and merely a token bill in compute. So the transferable value here is recognizing the shape rather than copying the method. **Do you have a problem where the answer sits inside a set too large for a person to read through, and where the filtering criteria can be written down?** If so, this process applies. If the hard part of your problem is forming the hypothesis itself, it will not help.

The Division of Labor Is Stated Specifically, and It Is the Line Worth Keeping

Anthropic says human scientists were involved in two things: **writing the initial prompt, and performing all laboratory work.** The model operated no experimental equipment; everything done at the bench was done by people. That sentence matters because it makes both a capability claim and a boundary claim. The capability claim: the long stretch of analysis between prompt and candidate list, the model walked on its own. The boundary claim: **wet lab work is still entirely human.** It also explains why Anthropic built its own laboratory. If the computational side can produce 20 candidates in 21 hours while validation queues for months, the bottleneck simply relocates to the bench. The company's own framing is that acceleration requires a new way of doing biology research, with agents collaborating with humans at every step — which meant building a lab. The research group was formed in spring 2026. The lab runs at BSL-1 and BSL-2 and handles no human pathogens. That belongs in any retelling, because it defines the scope of this work.

What to Wait For Is Independent Replication, Not the Next Announcement

The most useful advice here is to put the judgment point in the right place. The current strength of evidence is: a pre-print, plus the company's own account of its process, plus one outside researcher saying it merits further investigation. **A pre-print means it has not been peer reviewed**, and whether the finding could transform gene editing still requires independent testing, by the company's own statement. So what to wait for is not Anthropic's next announcement but **whether another lab independently reproduces the result, and whether ART's function gets worked out.** Until then, treating this as a substantial lead rather than a delivered breakthrough is the only defensible reading. As an aside, this site has two other pieces today on Anthropic and OpenAI cutting prices the same day. One company competing head-on over price while also publishing how automated and productive its own R&D has become looks like two unrelated stories, but they share a premise: **how far inference costs fall determines how many institutions can afford to run 950 agents for 21 hours.** Today's two kinds of news are two sides of one thing.

via: Anthropic's announcement, Unite.AI, Reuters via KSL, Investing.com